Evotec Enters Collaboration and License Pact with Pfizer
Evotec enters collaboration and license pact with Pfizer to focus on early discovery research for metabolic and infectious
Overview
Evotec SE, a life science company, announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Site of Research
The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics.
Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programmes.
Words from CBO: Evotec
Dr Matthias Evers, chief business officer at Evotec, commented: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec also contributes with its strong presence with more than 1,000 employees at our French sites, building a strong pipeline of medicines that matter. Focussing on diseases with severe unmet medical need and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.”
From medical lead France: Pfizer
Dr Luca Mollo, vice president and medical lead France at Pfizer, commented: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need.”
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!